Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | LDHA | P00338 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 4/20 | 0.55 |
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5217775 | 0.93 | GSK3B (0.56) | ALDH1A1CYP1A2LDHACA1CA2 | |
| SCHEMBL11522245 | 0.85 | KDM4E (0.61) | ALDH1A1CYP1A2LDHA | |
| SCHEMBL23295612 | 0.85 | HDAC3 (0.50) | ALDH1A1CYP1A2CA1CA2GSK3B | |
| SCHEMBL28548638 | 0.84 | NPC1 (0.52) | ALDH1A1CYP1A2CES2CES1MAPT | |
| SCHEMBL14435692 | 0.83 | LDHA (0.50) | ALDH1A1CYP1A2LDHACA1CA2 | |
| SCHEMBL28635043 | 0.83 | ALDH1A1 (0.43) | ALDH1A1CYP1A2LDHAPARP10POLB | |
| SCHEMBL7100665 | 0.82 | ALDH1A1 (0.63) | ALDH1A1CYP1A2CA1CA2GSK3B | |
| SCHEMBL5215355 | 0.82 | MAPT (0.52) | ALDH1A1CYP1A2CES2CES1POLB | |
| SCHEMBL7639644 | 0.81 | HTT (0.58) | ALDH1A1CYP1A2CA1CA2GSK3B | |
| SCHEMBL27885703 | 0.81 | ALDH1A1 (0.55) | ALDH1A1CYP1A2LDHACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964985-B2 | Anti-cancer compounds targeting Ral GTPases and methods of using the same | The Regents of the University of Colorado, a body corporate. (US) | 2024-04-23 | — | — | US | disclosed |
| US-11472812-B2 | Anti-cancer compounds targeting Ral GTPases and methods of using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2022-10-18 | — | — | US | disclosed |
| US-RE48557-E1 | Anti-cancer compounds targeting Ral GTPases and methods of using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200270263-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2020-08-27 | — | — | US | disclosed |
| US-20200255442-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2020-08-13 | — | — | US | disclosed |
| EP-3686202-A1 | 6-AMINO-1,3-DIMETHYL-4-(4-(TRIFLUOROMETHYL)PHENYL)-1,4-DIHYDROPYRANO [2,3-C]PYRAZOLE-5-CARBONITRILE AND RELATED COMPOUNDS AS RAL GTPASE INHIBITORS FOR TREATING CANCER METASTASIS | The Regents of the University of Colorado, a body corporate (US) | 2020-07-29 | — | — | EP | disclosed |
| US-10689392-B2 | Anti-cancer compounds targeting ral GTPases and methods of using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2020-06-23 | — | — | US | disclosed |
| US-10676480-B2 | Anti-cancer compounds targeting Ral GTPases and methods of using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2020-06-09 | — | — | US | disclosed |
| EP-3166609-B1 | 6-AMINO-1,3-DIMETHYL-4-(4-(TRIFLUOROMETHYL)PHENYL)-1,4-DIHYDROPYRANO [2,3-C]PYRAZOLE-5-CARBONITRILE AND RELATED COMPOUNDS AS RAL GTPASE INHIBITORS FOR TREATING CANCER METASTASIS | UNIV COLORADO REGENTS (US) | 2020-03-11 | — | — | EP | disclosed |
| US-10490748-B2 | Rectifying element, method for producing same, and wireless communication device | TORAY INDUSTRIES, INC. (JP) | 2019-11-26 | — | — | US | disclosed |
| US-6946481-B1 | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2005-09-20 | — | — | US | disclosed |
| EP-1119567-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-05-04 | — | — | EP | disclosed |
| EP-1170629-B1 | Silver halide multilayer color photographic material | FERRANIA SPA (IT) | 2004-12-01 | — | — | EP | disclosed |
| US-20020031735-A1 | Silver halide multilaye color photographic material | FERRANIA, S.P.A., | 2002-03-14 | — | — | US | disclosed |
| EP-1170629-A2 | Silver halide multilayer color photographic material | FERRANIA S.p.A. (IT) | 2002-01-09 | — | — | EP | disclosed |
| EP-1119567-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | disclosed |
| EP-1003740-A2 | PYRROLIDINE-3-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGOISTS | Abbott Laboratories (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-2000021955-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999006397-A2 | PYRROLIDINE-3-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1999-02-11 | — | — | WO | disclosed |
| US-5731434-A | CARDIOVASCULAR DISORDERS | ABBOTT LABORATORIES (US) | 1998-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964985-B2 | Anti-cancer compounds targeting Ral GTPases and methods of using the same | ARFGAP1, ARHGDIB, IQGAP1 | ALDH1A1 3045/4885CYP1A2 4837/4885LDHA 3626/4885 |
| US-20200255442-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | ARFGAP1, ARHGDIB, RALA | ALDH1A1 3496/4885CYP1A2 4854/4885LDHA 3415/4885 |
| US-10689392-B2 | Anti-cancer compounds targeting ral GTPases and methods of using the same | ARFGAP1, ARHGDIB, IQGAP1 | ALDH1A1 3045/4885CYP1A2 4837/4885LDHA 3626/4885 |
| US-20200270263-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | ARFGAP1, ARHGDIB, IQGAP1 | ALDH1A1 3045/4885CYP1A2 4837/4885LDHA 3626/4885 |
| US-10676480-B2 | Anti-cancer compounds targeting Ral GTPases and methods of using the same | ARFGAP1, ARHGDIB, RALA | ALDH1A1 3496/4885CYP1A2 4854/4885LDHA 3415/4885 |
| US-11472812-B2 | Anti-cancer compounds targeting Ral GTPases and methods of using the same | ARFGAP1, ARHGDIB, RALA | ALDH1A1 3496/4885CYP1A2 4854/4885LDHA 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.